Additional Pre-Specified Secondary Results on the Reduction of Ventricular Arrhythmias Presented at AHA from Vericel’s Positive Phase 2b ixCELL‑DCM Clinical Trial of Ixmyelocel-T
November 14, 2016 14:00 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cellular therapies for the treatment of severe diseases and...
Vericel Reports Third-Quarter 2016 Financial Results
November 07, 2016 16:05 ET
|
Vericel Corporation
Total Revenues of $10.9 Million Reported for the Quarter Conference Call Today at 4:30pm Eastern Time CAMBRIDGE, Mass., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a...
Vericel to Host Third-Quarter 2016 Earnings Webcast and Conference Call on November 7, 2016
October 31, 2016 08:00 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cellular therapies for the treatment of severe diseases and...
Vericel to Present at 2016 Cell & Gene Meeting on the Mesa
September 26, 2016 08:00 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Sept. 26, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of autologous cellular therapies for the treatment of severe diseases and conditions,...
Vericel to Present at Ladenburg Thalmann Healthcare Conference
September 21, 2016 08:00 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Sept. 21, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of autologous cellular therapies for the treatment of severe diseases and conditions,...
Vericel Enters into Expanded $20 Million Credit Facility and Term Loan with Silicon Valley Bank and MidCap Financial Services
September 12, 2016 08:00 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cellular therapies for the treatment of severe diseases and...
Vericel to Present Data at the American Heart Association’s Scientific Sessions 2016 on the Reduction of Ventricular Arrhythmias with Ixmyelocel-T in the ixCELL-DCM Clinical Trial
September 07, 2016 08:00 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cellular therapies for the treatment of severe diseases and...
Vericel Reports Second-Quarter 2016 Financial Results
August 08, 2016 16:05 ET
|
Vericel Corporation
Total Revenues of $12.8 Million Reported for the Quarter Conference Call Today at 4:30pm Eastern Time CAMBRIDGE, Mass., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a...
Vericel to Host Second-Quarter 2016 Earnings Webcast and Conference Call on August 8, 2016
August 01, 2016 07:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases...
Vericel to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
July 06, 2016 16:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., July 06, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and...